Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 3Glioma 2Glioblastoma 2Astrocytoma 2Sarcoma 1Peritoneal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Bone Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

Sunitinib 86Sorafenib 60Everolimus 47pazopanib 46Bevacizumab 46Nivolumab 44pembrolizumab 37aldesleukin 29Interferon-alpha 26Axitinib 24temsirolimus 23cabozantinib 20Interleukin-2 19Ipilimumab 16Interferon alpha-2 15Cyclophosphamide 15fludarabine phosphate 14Gemcitabine 14Peripheral Blood Stem Cell Transplantation 11Sirolimus 10Paclitaxel 10Erlotinib Hydrochloride 10avelumab 8Radiosurgery 8Docetaxel 8Cyclosporine 8Capecitabine 8tremelimumab 7lenvatinib 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Renal Cell × lentiviral minigene vaccine of COVID-19 coronavirus × Clear all
NCT00085436 2018-06-26

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Dartmouth-Hitchcock Medical Center

Phase 2 Completed
18 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡